Dyslipidemia: the untreated metabolic dysfunction in people with type 2 diabetes in Latin America. ARETAEUS study outcomes

ConclusionDyslipidemia treatment in patients with T2D was delayed despite its known deleterious effect on atherosclerosis development and β-cell mass/function. Anti-hyperglycemic treatment was not intensified when targets were not attained. This prescriptive inertia needs to be corrected because attainment of HbA1c treatment goals becomes more difficult, favoring the development of diabetes complications.
Source: Journal of Clinical and Translational Endocrinology - Category: Endocrinology Source Type: research